Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Q&A

Date

31 Mar 2023

Session

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Presenters

Heather Wakelee

Authors

H. Wakelee

Author affiliations

Stanford/US

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

31 Mar 2023

Strategies to overcome resistance to EGFR and ALK TKIs

Presenter: Mariana Brandão

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Moving EGFR and ALK TKIs into earlier stage disease

Presenter: Margarita Majem Tarruella

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Beyond ex19del and L858R: Update on EGFRex20 insertions and other uncommon EGFR mutations

Presenter: Xiuning Le

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast